Preclinical evidence has shown significant upregulation of ICAM-1 at atherosclerotic-prone sites in murine models of cardiovascular disease that are homozygous apolipoprotein E-deficient (ApoE−/−), particularly within the aorta (25, 26). This evidence concerns the gene APOE and cardiovascular disorder.